CA-CONFLUENT
12.5.2021 09:02:04 CEST | Business Wire | Press release
Confluent, Inc. , the platform to set data in motion, today announced Confluent for Kubernetes , the first platform purpose-built to bring cloud-native capabilities to data streams in private infrastructures. To make it easier and faster to harness the value of data in motion across an entire organization, Confluent drew on its expertise managing thousands of Apache Kafka® clusters in Confluent Cloud to offer the same cloud-native experience for on-premises environments. These cloud-native capabilities are key to running modern data platforms and are now available wherever an organization’s applications and data reside. Within minutes, it’s now possible to build a private cloud Kafka service that powers applications that are increasingly critical to how organizations thrive.
To win in today’s global economy, organizations must deliver exceptional customer experiences and data-driven, backend operations. This requires the ability to react, respond, and adapt to a continuous, ever-changing flow of data from across an organization in real time. This has driven the rapid rise of Kafka as a key enabler to helping companies cut across silos and process the flow of business events as they happen. However, given the high level of technical complexity, need for constant monitoring, and time-consuming custom tooling, self-managing Kafka is difficult and often takes large teams of specialized professionals. These challenges can result in costly project delays and inefficient resource investments, holding organizations back as they compete to innovate and win in a digital-first world.
“To compete in the digital realm, organizations need to quickly deliver personalized customer experiences and real-time operations, which are only possible with access to data from all environments and cloud-native advantages,” said Ganesh Srinivasan, Chief Product and Engineering Officer, Confluent. “For organizations that need to operate on premises, we’re bringing the benefits of cloud computing to their private infrastructure with Confluent for Kubernetes. Now, any company can build a private cloud service to move data across their business regardless of its environment.”
Confluent for Kubernetes – Bringing Benefits From the Leading Data in Motion Cloud Platform to On-Premises Environments
With the launch of Confluent for Kubernetes, Confluent brings together the cloud-native advantages learned from Confluent Cloud with the control and customization from self-managing their private infrastructure in on-premises environments. So whether an organization is transitioning to the cloud or needs to keep workloads on premises, they can take full advantage of Confluent for Kubernetes’ cloud-native capabilities, including a declarative API to deploy and operate Confluent. The platform also makes moving applications to the public cloud easier by seamlessly migrating workloads to wherever your business needs them with the ability to connect and share data with Confluent Cloud. By reimagining what is possible for private infrastructure with the capabilities of modern cloud computing, it is easier than ever for organizations to build and manage a private cloud Kafka service for moving data across a business.
- Enhanced reliability – As a cloud-native system, Confluent for Kubernetes intelligently detects if a process fails and will automatically restart processes or reschedule as necessary. Automated rack awareness spreads replicas of a partition across different racks, improving the availability of your brokers and limiting the risk of data loss. With automated reliability, organizations can minimize the risk of business disruption, reduce downtime costs, and limit data loss.
- Automated elasticity – Meet changing business demands with the ability to scale up using API-driven operations. The platform will automatically generate configurations, schedule and run new broker processes, and ensure data is balanced across brokers so that clusters can be efficiently utilized. With the ability to spin up and down Confluent clusters, organizations can control infrastructure costs while quickly scaling to meet their business needs.
- Simplified infrastructure management – A core concept of the cloud-native paradigm is the ability to focus on higher value activities that create business value rather than performing complex sequences of low-level infrastructure-related operations. Confluent for Kubernetes extends the Kubernetes API, enabling organizations to define the desired high-level state of clusters rather than manage all the low-level details. This infrastructure-as-code approach reduces operational burden and achieves a faster time to value, while enhancing security with standards that can be easily and consistently deployed across an organization.
Kafka Summit Europe 2021
Tune into Confluent Co-founder and CEO Jay Kreps’ keynote at Kafka Summit Europe on May 12 at 8:00 a.m. GMT to learn more about today’s news. Register now: https://kafkasummit.io/
For a deep dive into Confluent for Kubernetes, don’t miss this Kafka Summit Europe lightning talk happening today at 1 p.m. GMT: https://www.kafka-summit.org/sessions/gitops-for-kafka-with-confluent-for-kubernetes
Additional Resources
- For more details on how Confluent for Kubernetes works, check out our blog: https://www.confluent.io/blog/confluent-for-kubernetes-offers-cloud-native-kafka-automation/
- See how Confluent is helping its customers transform their businesses: https://www.confluent.io/customers/
- Learn more about Confluent: https://www.confluent.io/
- Join Confluent and apply for one of its open positions: https://www.confluent.io/careers/
About Confluent
Confluent is pioneering a fundamentally new category of data infrastructure focused on data in motion. Confluent’s cloud-native offering is the foundational platform for data in motion – designed to be the intelligent connective tissue enabling real-time data, from multiple sources, to constantly stream across the organization. With Confluent, organizations can meet the new business imperative of delivering rich, digital front-end customer experiences and transitioning to sophisticated, real-time, software-driven backend operations. To learn more, please visit www.confluent.io .
The preceding outlines our general product direction and is not a commitment to deliver any material, code, or functionality. The development, release, timing, and pricing of any features or functionality described may change. Customers should make their purchase decisions based upon services, features, and functions that are currently available. Confluent and associated marks are trademarks or registered trademarks of Confluent, Inc.
Apache® and Apache Kafka® are either registered trademarks or trademarks of the Apache Software Foundation in the United States and/or other countries. No endorsement by the Apache Software Foundation is implied by the use of these marks. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
